LAC: A Potential Drug Target and Biomarker for Diseases (G3938)

Target Name: LCT

NCBI ID: G3938

Content of Review Report on LCT Target / Biomarker

LCT

LAC: A Potential Drug Target and Biomarker for Diseases

Lactic Acid (LAC) is a molecule that plays a crucial role in many biological processes in the human body. It is a byproduct of fermentation and is found in various bodily fluids, including blood, saliva, and tears. LAC has been identified as a potential drug target and a biomarker for various diseases, including cancer, diabetes, and neurodegenerative disorders.

Drug Targets

LAC has been identified as a potential drug target due to its unique structure and various biological functions. One of the main reasons for its potential as a drug target is its ability to interact with various signaling pathways. LAC has been shown to interact with multiple signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

The TGF-β pathway is a key signaling pathway that regulates cell growth, differentiation, and inflammation. LAC has been shown to inhibit the activity of the TGF-β receptor, which is a key component of this pathway. This inhibition has been shown to have various therapeutic effects, including the inhibition of cancer cell growth and the regulation of cell differentiation.

The PI3K/Akt pathway is a signaling pathway that regulates cell survival and metabolism. LAC has been shown to interact with the PI3K/Akt pathway and has been shown to play a negative role in its regulation. This interaction has been shown to contribute to the anti-inflammatory effects of LAC, as well as its potential therapeutic effects in diseases such as cancer, neurodegenerative disorders, and diabetes.

The NF-kappa-B pathway is a signaling pathway that regulates inflammation and pain. LAC has been shown to interact with the NF-kappa-B pathway and has been shown to play a negative role in its regulation. This interaction has been shown to contribute to the anti -inflammatory and pain-relieving effects of LAC.

Biomarkers

LAC has also been identified as a potential biomarker for various diseases. One of the main reasons for its potential as a biomarker is its ability to be affected by various diseases and conditions, including cancer, diabetes, and neurodegenerative disorders.

LAC has been shown to be affected by various diseases and conditions, including cancer. LAC has been shown to have a negative impact on the growth and survival of cancer cells, and has been shown to be a potential therapeutic agent for cancer treatment.

LAC has also been shown to be affected by diabetes. LAC has been shown to have a negative impact on the growth and survival of insulin-dependent and -resistance mouse diabetic rats, and has been shown to be a potential therapeutic agent for diabetes treatment.

LAC has also been shown to be affected by neurodegenerative disorders. LAC has been shown to have a negative impact on the growth and survival of neurodegenerate mouse models, and has been shown to be a potential therapeutic agent for neurodegenerative disorders.

Conclusion

In conclusion, LAC is a molecule that has been identified as a potential drug target and biomarker for various diseases. Its ability to interact with multiple signaling pathways and its potential therapeutic effects make it an attractive candidate for further research and development. Further studies are needed to fully understand the unique mechanisms of LAC and its potential as a drug target and biomarker.

Protein Name: Lactase

Functions: Broad specificity glycosidase of the intestinal brush border membrane that hydrolyzes lactose, the main sugar in mammalian milk, to produce D-glucose and D-galactose (PubMed:3929764, PubMed:9762914, PubMed:12594539, PubMed:16400612). The mature protein is composed of two domains that catalyze the hydrolysis of beta-glucopyranosides and beta-galactopyranosides, with a preference for hydrophilic aglycones (in lactose and cellobiose) for one domain and hydrophobic aglycones (in phlorizin and glycosylceramides) for the other (PubMed:3929764, PubMed:9762914, PubMed:12594539)

The "LCT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets